{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:38:40Z","timestamp":1792175920543,"version":"4.4.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.cgh.2023.01.018","type":"journal-article","created":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T21:44:27Z","timestamp":1675115067000},"page":"2597-2605.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Saroglitazar, a Dual PPAR \u03b1\/\u03b3 Agonist, Improves Atherogenic Dyslipidemia in Patients With Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7392-7489","authenticated-orcid":false,"given":"Mohammad Shadab","family":"Siddiqui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deven","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farheen","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiv Kumar","family":"Sarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cisneros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer","family":"Gawrieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6258-6559","authenticated-orcid":false,"given":"Taufik","family":"Momin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Duseja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun J.","family":"Sanyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2023.01.018_bib1","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/hep.21327","article-title":"Long-term follow-up of patients with NAFLD and elevated liver enzymes","volume":"44","author":"Ekstedt","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.01.018_bib2","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/hep.23314","article-title":"Decreased survival of subjects with elevated liver function tests during a 28-year follow-up","volume":"51","author":"S\u00f6derberg","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.01.018_bib3","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2023.01.018_bib4","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJMra0912063","article-title":"Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease","volume":"363","author":"Targher","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2023.01.018_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135329","article-title":"Nonalcoholic fatty liver disease is independently associated with early left ventricular diastolic dysfunction in patients with type 2 diabetes","volume":"10","author":"Mantovani","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.cgh.2023.01.018_bib6","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/lt.26069","article-title":"Atherogenic dyslipidemia after liver transplantation: mechanisms and clinical implications","volume":"27","author":"Syed","year":"2021","journal-title":"Liver Transpl"},{"key":"10.1016\/j.cgh.2023.01.018_bib7","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.cgh.2014.10.008","article-title":"Severity of nonalcoholic fatty liver disease and progression to cirrhosis associate with atherogenic lipoprotein profile","volume":"13","author":"Siddiqui","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.01.018_bib8","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1002\/hep.30410","article-title":"The interplay between nonalcoholic fatty liver disease and atherosclerotic heart disease","volume":"69","author":"Patel","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.01.018_bib9","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1016\/j.cgh.2020.09.039","article-title":"Association between lipoprotein particles and atherosclerotic events in nonalcoholic fatty liver disease","volume":"19","author":"Patel","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.01.018_bib10","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/hep.30518","article-title":"Small dense low-density lipoprotein cholesterol predicts cardiovascular events in liver transplant recipients","volume":"70","author":"Siddiqui","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.01.018_bib11","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1001\/jama.1988.03410130125037","article-title":"Low-density lipoprotein subclass patterns and risk of myocardial infarction","volume":"260","author":"Austin","year":"1988","journal-title":"JAMA"},{"key":"10.1016\/j.cgh.2023.01.018_bib12","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/ATVBAHA.114.303284","article-title":"Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study","volume":"34","author":"Hoogeveen","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cgh.2023.01.018_bib13","article-title":"Interplay between dyslipidemia, atherogenic lipoproteins, and residual atherogenic risk in liver transplant recipients","author":"Tseng","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.01.018_bib14","first-page":"340","article-title":"High-dose statin therapy with rosuvastatin reduces small dense LDL and MDA-LDL: the Standard versus high-dose therApy with Rosuvastatin for lipiD lowering (SARD) trial","volume":"67","author":"Nishikido","year":"2016","journal-title":"J\u00a0Cardiol"},{"key":"10.1016\/j.cgh.2023.01.018_bib15","doi-asserted-by":"crossref","first-page":"128","DOI":"10.5551\/jat.14.128","article-title":"The effects of statin and fibrate on lowering small dense LDL-cholesterol in hyperlipidemic patients with type 2 diabetes","volume":"14","author":"Tokuno","year":"2007","journal-title":"J\u00a0Atheroscler Thromb"},{"key":"10.1016\/j.cgh.2023.01.018_bib16","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/lt.25067","article-title":"Utilization of aspirin and statin in management of coronary artery disease in patients with cirrhosis undergoing liver transplant evaluation","volume":"24","author":"Patel","year":"2018","journal-title":"Liver Transpl"},{"key":"10.1016\/j.cgh.2023.01.018_bib17","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1007\/s10620-015-4000-6","article-title":"Statins are underutilized in patients with nonalcoholic fatty liver disease and dyslipidemia","volume":"61","author":"Blais","year":"2016","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2023.01.018_bib18","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/S0140-6736(10)61272-X","article-title":"Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study: a post-hoc analysis","volume":"376","author":"Athyros","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2023.01.018_bib19","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1517\/14656566.2015.1009894","article-title":"Saroglitazar for the treatment of dyslipidemia in diabetic patients","volume":"16","author":"Joshi","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.cgh.2023.01.018_bib20","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1016\/j.cgh.2020.10.051","article-title":"A\u00a0phase 2 double blinded, randomized controlled trial of saroglitazar in patients with nonalcoholic steatohepatitis","volume":"19","author":"Siddiqui","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2023.01.018_bib21","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.31843","article-title":"Saroglitazar, a PPAR-\u03b1\/\u03b3 agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial","volume":"74","author":"Gawrieh","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.01.018_bib22","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2023.01.018_bib23","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-019-0884-3","article-title":"New dual peroxisome proliferator activated receptor agonist - saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence","volume":"18","author":"Kaul","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.cgh.2023.01.018_bib24","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A\u00a0randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2023.01.018_bib25","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1021\/acs.jmedchem.7b01285","article-title":"Design, synthesis, and evaluation of a novel series of indole sulfonamide peroxisome proliferator activated receptor (PPAR) \u03b1\/\u03b3\/\u03b4 triple activators: discovery of lanifibranor, a new antifibrotic clinical candidate","volume":"61","author":"Boubia","year":"2018","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.cgh.2023.01.018_bib26","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.136","article-title":"Saroglitazar, a novel PPAR\u03b1\/\u03b3 agonist with predominant PPAR\u03b1 activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models","volume":"3","author":"Jain","year":"2015","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.cgh.2023.01.018_bib27","doi-asserted-by":"crossref","first-page":"13919","DOI":"10.1073\/pnas.241410198","article-title":"Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors","volume":"98","author":"Xu","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cgh.2023.01.018_bib28","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/liv.13634","article-title":"Dual PPAR\u03b1\/\u03b3 agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models","volume":"38","author":"Jain","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.cgh.2023.01.018_bib29","article-title":"The PPAR \u03b1\/\u03b3 agonist saroglitazar improves insulin resistance and steatohepatitis in a diet induced animal model of nonalcoholic fatty liver disease","volume":"10","author":"Kumar","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.cgh.2023.01.018_bib30","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.atherosclerosis.2006.05.007","article-title":"LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"192","author":"Mora","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cgh.2023.01.018_bib31","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.2337\/dc07-1088","article-title":"Intrahepatic fat accumulation and alterations in lipoprotein composition in obese adolescents: a perfect proatherogenic state","volume":"30","author":"Cali","year":"2007","journal-title":"Diabetes Care"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356523000770?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356523000770?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:43:44Z","timestamp":1761543824000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356523000770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1542356523000770"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2023.01.018","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Saroglitazar, a Dual PPAR \u03b1\/\u03b3 Agonist, Improves Atherogenic Dyslipidemia in Patients With Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2023.01.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the AGA Institute","name":"copyright","label":"Copyright"}]}}